Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery.

Henry Brem is a Neurosurgery provider in Baltimore, Maryland. Dr. Brem is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Gliosarcoma, Glioma, Brain Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Osteotomy.

David Kamson is an Oncologist in Baltimore, Maryland. Dr. Kamson is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Brain Tumor, Glioblastoma, Gliosarcoma, Metastatic Brain Tumor, and Hormone Replacement Therapy (HRT).

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy.

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

John Laterra is a Neurologist in Baltimore, Maryland. Dr. Laterra is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Laterra is currently accepting new patients.

Alessandro Olivi is a Neurosurgery provider in Baltimore, Maryland. Dr. Olivi is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Microvascular Decompression, and Craniectomy.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor.

Karisa Schreck is co-director of the BRAF Brain Tumor Center at Johns Hopkins. Her research focuses on the development of small-molecule targeted therapies for patients with primary brain tumors. Dr. Schreck has specific expertise in the treatment of BRAF gene mutations. As such, she works with Christine Pratilas’ laboratory to investigate resistance mechanisms to BRAF-targeted therapy. Dr. Schreck also writes and runs clinical trials for novel targeted agents through the Comprehensive Brain Tumor Center and the Alliance for Clinical Trials in Oncology. Dr. Schreck is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Glioma, Brain Tumor, Astrocytoma, and Glioblastoma.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Dr. Gary Gallia's specialty is endoscopic endonasal surgical approaches to skull base pathologies with a focus on neurosurgical oncology. He utilizes the latest techniques in preoperative imaging, computer-guided surgical navigation, intraoperative monitoring, and minimally invasive and Neuroendoscopy approaches in the management of patients with benign and malignant brain tumors, metastatic tumors to the brain, skull base neoplasms, and pituitary tumors. He is the director of the Neurosurgery Skull Base Center and surgical director of the Johns Hopkins Pituitary Center. Dr. Gary Gallia graduated summa cum laude from the Gibbons Scholar MD/PhD program at Jefferson Medical College and Thomas Jefferson University. He completed his general surgery internship at The Johns Hopkins Hospital where he was awarded surgical intern of the year. He then completed his neurological surgery residency and a postdoctoral fellowship in neuro-oncology at The Johns Hopkins Hospital. Following residency, he completed a minimally invasive and endoscopic neurosurgery fellowship with Dr. Charles Teo at the Prince of Wales Private Hospital and Sydney Children's Hospital in Sydney, Australia. Dr. Gallia is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Olfactory Neuroblastoma, Chordoma, Pituitary Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Awake Craniotomy.

Christopher Jackson is a neurosurgeon who specializes in brain tumors and cerebrovascular disorders, including glioma, meningioma, acoustic neuroma, trigeminal neuralgia, brain metastasis, arteriovenous malformation, and aneurysms. He is the director of the Acoustic Neuroma Center. Dr. Jackson earned his medical degree from the Johns Hopkins University School of Medicine, where he also completed his neurosurgical residency. During his residency, Dr. Jackson was honored with multiple distinctions, including the Frank L. Coulson Jr. Award for Clinical Excellence, the Irving J. Sherman Award for Resident Achievement, the Harvey Cushing Hunterian Research Award, and was elected to Alpha Omega Alpha. Dr. Jackson is an active researcher who has published over 35 peer-reviewed articles on brain tumor and cerebrovascular immunology. His laboratory focuses on how brain tumors evade the immune system and become resistant to immunotherapy. Additionally, Dr. Jackson’s laboratory explores the formation of cerebral aneurysms and inflammatory complications of cerebral aneurysm rupture. Dr. Jackson is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Trigeminal Neuralgia, Meningioma, Dysembryoplastic Neuroepithelial Tumors (DNET), Rhizotomy, and Microvascular Decompression.

Dr. Debraj “Raj” Mukherjee’s clinical focus is the treatment of patients with primary and metastatic brain lesions. His clinical work and research emphasize the development of individual treatment plans that optimize survival and quality of life in all patients. After receiving his medical degree from Dartmouth Medical School, Dr. Mukherjee was recruited to Johns Hopkins, where he studied epidemiology, biostatistics and clinical design at the Johns Hopkins Bloomberg School of Public Health and served as Director of the Neuro-Oncology Surgical Outcomes Laboratory in the Department of Neurosurgery. Dr. Mukherjee completed neurosurgery residency at Cedars-Sinai Medical Center, where he was named a Robert Wood Johnson Foundation Health & Society Scholar. He completed an open and endoscopic skull base fellowship with the Center for Skull Base Surgery at University of Pittsburgh Medical Center, where he was a Copeland Scholar. Throughout his career, Dr. Mukherjee has led patient-centered research pursuits in neuro-oncology including development of a national registry for patients with brain tumors, creation of disease-specific quality of life instruments for patients with skull base tumors, and development of innovative clinical trials in neuro-oncology. He leads the Meningioma, Brain Metastasis, and Neurosurgical Oncology centers at Johns Hopkins Medicine, and he serves as Assistant Residency Program Director for one of the largest neurosurgical training programs in the country. His work has been supported by the American Medical Association, Glioblastoma Foundation, National Institute on Aging, and National Cancer Institute. Dr. Mukherjee can be contacted at drraj@jhmi.edu. Dr. Mukherjee is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Meningioma, Pituitary Tumor, Brain Tumor, Awake Craniotomy, and Laminectomy.

Chetan Bettegowda is the director of the Johns Hopkins Department of Neurosurgery. He offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors. Dr. Bettegowda is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression.

Sahaja Acharya is the Director of Pediatric Radiation Oncology within the Department of Radiation Oncology and Molecular Radiation Sciences. She specializes in pediatric brain tumors, pediatric sarcomas, and adult sarcomas. She is also the Associate Director for the Radiation Oncology Residency Program. She leads the Pediatric Radiation Oncology program at the Johns Hopkins Hospital and treats patients at both Johns Hopkins Hospital and Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, pediatric malignancies, and adult sarcoma. She is the Principal Investigator on external grants from ASCO Conquer Cancer, the Department of Defense, and the Carson Leslie Foundation. She is also the Principal Investigator of phase II pediatric brain tumor clinical trials. She has been invited to participate in multiple national and international guideline committees and regularly lectures on pediatric malignancies and proton therapy. Dr. Acharya received her Bachelor's in Chemistry and Political Science from Stanford University and her medical degree from Saint Louis University. She completed radiation oncology residency at Washington University in St. Louis. Dr. Acharya is rated as an Advanced provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Brain Tumor, Gliomatosis Cerebri, Glioma, and Posterior Fossa Tumor.

Alan R. Cohen is the director of pediatric neurosurgery at Johns Hopkins Children’s Center in Baltimore, Maryland, and one of the top pediatric neurosurgeons in the country. His area of specialty is treating infants and children diagnosed with brain tumors. Dr. Cohen’s goal is to get his patients back to being a kid again. He has a patient-centered approach to caring for each of his patients, working closely with the child’s family at every stage of the decision-making process. Dr. Cohen sees patients in the neurosciences clinic located in the Levi Watkins, Jr., M.D., Outpatient Center. As the Carson-Spiro Professor of Pediatric Neurosurgery, Dr. Cohen is a leader in developing minimally invasive techniques to enhance the safety and efficacy of selected pediatric neurosurgical procedures. He serves as director of the Minimally Invasive Neurosurgery Laboratory at Johns Hopkins and directs the Minimally Invasive Neurosurgery Fellowship Program. His lab focuses on developing novel instruments and surgical approaches. He has authored more than 200 peer-reviewed journal articles and book chapters, and published two textbooks. He has given approximately 330 national and international presentations, and has been an invited visiting professor at 50 medical centers. He is past president of the Society of Neurological Surgeons, the American Society of Pediatric Neurosurgeons and the AANS/CNS Section on Pediatric Neurological Surgery. He is past vice president of the American Academy of Neurological Surgery, a past director of the American Board of Neurological Surgery and current director of the American Board of Pediatric Neurological Surgery. Patient Reviews Hear what patients have to say about Dr. Cohen’s care: • Healthgrades Patient Reviews • Vitals Patient Reviews. Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Arachnoid Cysts, Meningocele, Hydrocephalus, Endoscopy, and Cerebral Artery Bypass Surgery.

William Regine is a Radiation Oncologist in Baltimore, Maryland. Dr. Regine is rated as an Advanced provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Pancreatic Cancer, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Anal Cancer.

Jordina Rincon-Torroella is a fellowship-trained neurosurgeon specializing in the surgical treatment of benign and malignant tumors of the brain and skull base, such as meningiomas, gliomas, pituitary tumors and metastatic brain tumors, to name a few. Dr. Rincon-Torroella earned her medical degree from the University of Barcelona medical school. She completed a postdoctoral fellowship in neurosurgical oncology at Johns Hopkins University, where she remained for residency training in neurosurgery. She completed an additional postdoctoral fellowship in cancer research and drug development at Johns Hopkins in the Ludwig Center under the mentorship of neurosurgeon Chetan Bettegowda and molecular biologist and geneticist Bert Vogelstein. Active in clinical research since 2010, Dr. Rincon-Torroella has published numerous research papers. She is also a peer reviewer for several journals and has edited two books, most recently The Neurosurgical Consult Book. Dr. Rincon-Torroella is fluent in Catalan, English and Spanish. Dr. Torroella is rated as an Advanced provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Subependymoma, Ependymoma, Brain Tumor, Laminectomy, and Craniectomy.

Dr. Eric Jackson specializes in the evaluation and treatment of patients with a broad range of neurosurgical disorders, including congenital malformations of the brain and spine, hydrocephalus (including endoscopic treatment), chiari malformation, craniosynostosis, spinal dysraphism/tethered cord, brain and spinal cord tumors, and traumatic brain injuries. He is the Principal Investigator for several multi-institution research studies, including: Hydrocephalus Clinical Research Network: currently investigating endoscopic surgery vs shunting for the treatment of hydrocephalus in infants in a $10M randomized trial funded by the NIH Park Reeves Syringomyelia Research Consortium Advancing the treatment for pediatric craniopharyngioma, identifying biological targets for molecular therapy A multi-institutional trial investigating a non-invasive eye tracking device for assessing increased intracranial pressure. Dr. Jackson is rated as an Experienced provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Hydrocephalus, Chiari Malformation, Chiari Malformation Type 2, Posterior Fossa Decompression, and Endoscopy.